Apollon Wealth Management LLC Purchases Shares of 80,025 Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX)

Apollon Wealth Management LLC acquired a new position in Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 80,025 shares of the company’s stock, valued at approximately $52,000. Apollon Wealth Management LLC owned 1.58% of Quoin Pharmaceuticals as of its most recent SEC filing.

Insiders Place Their Bets

In other Quoin Pharmaceuticals news, Director Anthony James Culverwell purchased 100,000 shares of the firm’s stock in a transaction on Monday, December 23rd. The shares were acquired at an average cost of $0.45 per share, with a total value of $45,000.00. Following the completion of the acquisition, the director now directly owns 100,317 shares in the company, valued at $45,142.65. The trade was a 31,545.74 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Gordon Dunn acquired 122,221 shares of the company’s stock in a transaction dated Monday, December 23rd. The stock was acquired at an average cost of $0.45 per share, with a total value of $54,999.45. Following the purchase, the chief financial officer now owns 151,077 shares of the company’s stock, valued at approximately $67,984.65. This trade represents a 423.55 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 777,777 shares of company stock worth $350,000. Company insiders own 3.70% of the company’s stock.

Quoin Pharmaceuticals Trading Down 6.8 %

Shares of NASDAQ:QNRX opened at $0.31 on Friday. Quoin Pharmaceuticals, Ltd. has a 12-month low of $0.28 and a 12-month high of $6.18. The company has a market cap of $1.56 million, a PE ratio of -0.08 and a beta of 1.72. The stock has a 50 day moving average of $0.52 and a 200 day moving average of $0.59.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.